Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$738.00
-$6.50 (-0.9%)
Closing Price on November 22, 2024
REGN Articles
Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.
Published:
Thursday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include Crocs, Halliburton, Nuance Communications, Staples and Yelp.
Published:
The continued strong insider buying last week into the teeth of a stock market that has hitting all-time highs continues to be a bullish sign for investors.
Published:
One sector that could be poised to do well could be the biotech arena, and the team at RBC has five top stocks for investors to focus on as best ideas.
Published:
Credit Suisse has released a biotech research report that has their top picks for upside potential in the biotech segment for 2015.
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers short and...
Published:
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.
Published:
ThinkstockIn what was yet another very volatile week for the markets, insider selling and insider buying has been active. We have evaluated some of the top insider selling transactions this last...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms on Monday, July 21, 2014. They include Apple, ARM Holdings, DaVita Healthcare, General Electric, GoPro and Itron.
Published:
ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors to buy the top biotech...
Published:
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
Published:
A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Here are the top large cap biotech stocks to buy at...
Published:
Last Updated:
A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as a "return to normalcy" following the roller coaster ride of early 2014.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street on Wednesday, April 16, 2014. They include Control4, Cree, NetApp, Twitter, Yahoo! and Yelp.
Published: